SpinChip Diagnostics AS (a bioMérieux Company)

SpinChip Diagnostics AS is a Norwegian biotechnology firm that specializes in developing and commercializing a Point of Care (POC) platform for in vitro diagnostics (IVD). Founded in 2012, the company focuses on providing lab-quality diagnostic testing directly at the patient's side, which enables immediate clinical decisions and enhances healthcare efficiency. The core product, the SpinChip all-in-one platform, is recognized for its high accuracy, sensitivity, and rapid turnaround time. It is particularly effective in testing for cardiac markers such as high-sensitive troponin I, N-terminal pro-B-type natriuretic peptide, and D-Dimer. SpinChip is committed to expanding its testing menu to address other critical clinical areas. The company operates with a focus on minimizing harm to people and the environment while ensuring cost-effective operations and future profitability. In January 2025, SpinChip Diagnostics was acquired by bioMérieux, a leader in in vitro diagnostics, to enhance its POC offerings. This partnership aims to accelerate the development and market introduction of its platform and assays, starting with the hs-TnI assay, which is undergoing clinical validation and CE marking application.

• Employees 50
• Founded 2012
• Total Funding $18179797